Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | LYN | P07948 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28000245 | 0.83 | KDM1A (0.37) | KDM1AMAOBOPRL1HRH3L3MBTL3 | |
| SCHEMBL1443184 | 0.80 | LMNA (0.35) | SMN1; SMN2 | |
| SCHEMBL28096462 | 0.80 | SLC18A3 (0.56) | OPRL1CYP2D6CYP2C19CYP2C9HRH3 | |
| SCHEMBL28876897 | 0.80 | SLC18A3 (0.51) | OPRL1CYP2D6CYP2C19HRH3L3MBTL3 | |
| SCHEMBL5313779 | 0.78 | IRAK4 (0.42) | KDM1AMAOBOPRL1CYP3A4CYP2C9 | |
| SCHEMBL28770195 | 0.78 | HRH3 (0.44) | KDM1AMAOBOPRL1CYP2D6CYP2C19 | |
| SCHEMBL24524 | 0.78 | — | — | |
| SCHEMBL5790547 | 0.76 | HPGD (0.44) | CYP2D6CYP2C19L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL27709432 | 0.76 | CYP2D6 (0.65) | KDM1AMAOBOPRL1CYP2D6CYP2C19 | |
| SCHEMBL2466664 | 0.74 | HRH3 (0.50) | KDM1AMAOBOPRL1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2686313-B1 | BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2016-02-03 | — | — | EP | disclosed |
| EP-2545047-B9 | HETEROCYCLIC INHIBITORS OF GLUTAMINYL CYCLASE (QC, EC 2.3.2.5) | PROBIODRUG AG (DE) | 2015-06-10 | — | — | EP | disclosed |
| EP-2545047-B1 | HETEROCYCLIC INHIBITORS OF GLUTAMINYL CYCLASE (QC, EC 2.3.2.5) | PROBIODRUG AG (DE) | 2014-04-23 | — | — | EP | disclosed |
| EP-2686313-A1 | BENZ IMIDAZOLE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2014-01-22 | — | — | EP | disclosed |
| US-8530670-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-10 | — | — | US | disclosed |
| US-8420828-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-04-16 | — | — | US | disclosed |
| EP-2545047-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINYL CYCLASE (QC, EC 2.3.2.5) | Probiodrug AG (DE) | 2013-01-16 | — | — | EP | disclosed |
| US-20120283259-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2012-11-08 | — | — | US | disclosed |
| US-20120237475-A1 | Novel Inhibitors | PROBIODRUG AG (DE) | 2012-09-20 | — | — | US | disclosed |
| WO-2012123563-A1 | BENZ IMIDAZOLE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-09-20 | — | — | WO | disclosed |
| US-8269019-B2 | Inhibitors | PROBIODRUG AG (DE) | 2012-09-18 | — | — | US | disclosed |
| WO-2011110613-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINYL CYCLASE (QC, EC 2.3.2.5) | PROBIODRUG AG (DE) | 2011-09-15 | — | — | WO | disclosed |
| US-20110224254-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224254-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | KDM1A 932/4885MAOB 1094/4885OPRL1 3644/4885 |
| US-20120237475-A1 | Novel Inhibitors | GLS, NQO2, GLS2 | KDM1A 1924/4885MAOB 1800/4885OPRL1 3522/4885 |
| US-20120283259-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | KDM1A 932/4885MAOB 1094/4885OPRL1 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.